Vastatin, a fragment derived from
type VIII collagen, is one of the least studied
collagen-derived matrikines.
Vastatin can be detected in serum but little is known regarding the relevance of serum
vastatin in
colorectal cancer (CRC). In this study, serum
vastatin was measured (ELISA) in 67 healthy controls and 48 CRC patients prior to resection and compared to clinicopathological parameters and serum
biomarkers of stromal reactivity (C3M, VICM). Impact of resection and
chemotherapy were evaluated by comparing baseline values with a 3-month follow-up sample (n = 23). Serum
vastatin was detectable in 114 of 115 subjects. At baseline
vastatin was elevated in CRC compared to controls (P < 0.001) with a diagnostic accuracy (AUROC) of 0.865, p < 0.0001.
Vastatin correlated with age in controls but not in patients with CRC; no association was seen with clinicopathological parameters.
Vastatin was independently associated with C3M (stepwise linear regression coefficient 0.25, p = 0.046). Overall, no difference was seen in
vastatin levels between baseline and follow-up. In conclusion,
vastatin is elevated in serum from patients with CRC and correlate with interstitial matrix degradation (C3M). This indicates that
vastatin is linked to stromal reactivity and suggests that
vastatin has
biomarker potential in CRC. The association with clinicopathological parameters and treatment effect needs further evaluation.